Viana Ana Carolina Leite, Goulart Eugênio Marcos Andrade, Gontijo Bernardo, Bittencourt Flávia Vasques
Dermatology Unity - Hospital das Clinicas - Universidade Federal de Minas Gerais (UFMG) - Belo Horizonte (MG), Brazil.
Department of Pediatrics - School of Medicine, Universidade Federal de Minas Gerais (UFMG) - Belo Horizonte (MG), Brazil.
An Bras Dermatol. 2017 Mar-Apr;92(2):200-205. doi: 10.1590/abd1806-4841.20175176.
: Large congenital melanocytic nevus (LCMN) is considered a risk factor for melanoma, although the magnitude of this risk is controversial.
: To evaluate the risk of melanoma development in patients with LCMN seen at a dermatology referral center in Brazil during a twelve-year period. To the best of our knowledge, there are no published similar studies on large congenital melanocytic nevus in South America.
: Our prospective cohort included only patients with congenital nevi ≥20cm. The cumulative risk of developing melanoma and the standardized morbidity ratio were calculated for patients followed up prospectively for at least 1 month.
: Sixty-three patients were enrolled in this study. One patient who developed melanoma prior to enrollment was excluded, and five were eliminated because of insufficient follow-up time. Mean follow-up for the remaining 57 patients was 5.5 years (median 5.2 years). Median age of entry into the study was 2.6 years. Most patients (75.4%) underwent only clinical observation. Melanomas occurred in 2 (3.5%) patients. Five-year cumulative risk for melanoma was 4.8% (95% CI: 1.9-11.5%). Standardized morbidity ratio was 1584 (95% CI: 266-5232, p<0.001).
: The small sample size reduces the accuracy of risk estimates.
: This study analyzed prospectively for the first time data from South America demonstrating that patients with LCMN have a higher risk of developing melanoma than the general population (p<0.001).
大先天性黑素细胞痣(LCMN)被认为是黑色素瘤的一个危险因素,尽管这种风险的程度存在争议。
评估在巴西一家皮肤科转诊中心就诊的LCMN患者在12年期间发生黑色素瘤的风险。据我们所知,南美洲尚无关于大先天性黑素细胞痣的类似研究发表。
我们的前瞻性队列仅纳入先天性痣≥20cm的患者。计算至少随访1个月的患者发生黑色素瘤的累积风险和标准化发病比。
本研究纳入63例患者。1例在入组前发生黑色素瘤的患者被排除,5例因随访时间不足被剔除。其余57例患者的平均随访时间为5.5年(中位数5.2年)。入组研究的中位年龄为2.6岁。大多数患者(75.4%)仅接受临床观察。2例(3.5%)患者发生黑色素瘤。黑色素瘤的5年累积风险为4.8%(95%CI:1.9 - 11.5%)。标准化发病比为1584(95%CI:266 - 5232,p<0.001)。
样本量小降低了风险估计的准确性。
本研究首次对来自南美洲的数据进行前瞻性分析,表明LCMN患者发生黑色素瘤的风险高于一般人群(p<0.001)。